Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with…

Cohort studyKorean journal of ophthalmology : KJO· Jul 2026

Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with Neovascular Age-Related Macular Degeneration.

Seungmin Choi, Jinsoo Kim, Min Seon Park … Bum-Joo Cho

RetinaCohort studyTreatmentQ2IF 1.3

Vision improved most 3 months after starting anti-VEGF injections for wet macular degeneration.

Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with Neovascular Age-Related Macular Degeneration.

Seungmin Choi … Bum-Joo Cho

Korean journal of ophthalmology · Jul 2026 · Q2 in Ophthalmology

Purpose

To evaluate the long-term real-world treatment outcome of intravitreal ranibizumab and aflibercept injections in pseudophakic eyes with neovascular age-related macular degeneration (nAMD), independently of the effect of cataract progression.

Methods

Medical records of pseudophakic patients with nAMD who were treatment-naïve, underwent intravitreal injection of ranibizumab or aflibercept between March 2010 and August 2023, and then were followed up for at least 1 year were retrospectively reviewed.

n = 93 patients

Results

vision-quality reading check improved most three months after starting treatment

Baseline

51letter

3 months

57.4letter

1 year

53letter

2 years

52.9letter

More results

In contrast, the mean central subfield thickness significantly decreased from 351.2 ± 114.6 μm to 230.7 ± 93.5 μm at 3 months, followed by a mild increase to 271.8 ± 117.1 μm at 1 year, and remained stable at 271.4 ± 160.5 μm at 2 years.

Thereafter, central subfield thickness gradually decreased reaching 251.7 ± 125.2 μm by the fifth year.

More results

There were no statistically significant differences in visual acuity or central subfield thickness between the ranibizumab and aflibercept groups throughout the period.

“

Conclusion

For eyes with sustained long-term follow-up, the visual outcomes of pseudophakic patients with nAMD, unaffected by cataract progression, were maintained at a good level above baseline over 4 years after intravitreal injection in the real-world, while central subfield thickness decreased consistently from 2 to 5 years after treatment.

Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with Neovascular Age-Related Macular Degeneration.

Real-World Treatment Outcome of Intravitreal Ranibizumab and Aflibercept in Pseudophakic Eyes with Neovascular Age-Related Macular Degeneration.

Related papers